Polaris Taiwan Subsidiary TDW To Begin Phase III Trials Of Liver Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Phase III clinical trials are slated to start next year on anti-cancer drug ADI-PEG 20 by U.S.-based Polaris Group's Taiwan subsidiary TDW Pharmaceuticals following successful Phase II trials that included recovery by a cancer patient deemed to have six months to live several years ago
You may also be interested in...
After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III
With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.
After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III
With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.
Taiwan Creates National Vaccine Fund To Stabilize National Supplies
HONG KONG - Taiwan plans to create a national vaccine fund as early as next year to stabilize the country's supply and streamline decisions on new purchases